NeuBase Therapeutics, Inc. (NBSE)
$0.182
-0.00 (-0.27%)
Rating:
Recommendation:
-
| Symbol | NBSE |
|---|---|
| Price | $0.182 |
| Beta | 0.851 |
| Volume Avg. | 0.46M |
| Market Cap | 6.153M |
| Shares () | - |
| 52 Week Range | 0.1206-1.45 |
| 1y Target Est | - |
| DCF Unlevered | NBSE DCF -> | |
|---|---|---|
| DCF Levered | NBSE LDCF -> | |
| ROE | -54.86% | Strong Sell |
| ROA | -58.91% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 40.38% | Neutral |
| P/E | -0.19 | Neutral |
| P/B | 0 | Neutral |
Latest NBSE news
About
Download (Excel)Dr. Dietrich A. Stephan Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.